Evidence map›Paper›PMID 40564074›Full record

ReviewBiomedicines2025

The Potential of Matrine in the Treatment of Breast Cancer: A Review.

Yumin Yang, Yufeng Li, Shanshan Liao, Pan Gao, Jie Tian, Cheng Fu, Xuhua Qin, Shenrui Jin

Abstract readReview
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yumin YangCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Yufeng LiCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Shanshan LiaoCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Pan GaoCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Jie TianCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Cheng FuCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Xuhua QinCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.ORCID 0000-0002-9933-0450
Shenrui JinSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.

Funding

the studio of Zu Lun Li 003112011013Xing lin Scholar JSZX2019004
6 · The paper itself

Abstract

Breast cancer ranks as the fifth-most-prevalent malignancy worldwide, characterized by high heterogeneity and multifactorial etiology across molecular subtypes. Despite advancements in conventional therapies, including surgery and chemotherapy, persistent challenges such as treatment-related adverse effects and acquired drug resistance necessitate alternative therapeutic strategies. Matrine, a naturally occurring alkaloid derived from Sophora flavescens, has demonstrated significant anticancer potential through multiple mechanisms. Experimental evidence indicates that matrine exerts inhibitory effects on tumor cell proliferation, promotes apoptosis, and attenuates metastatic progression via modulation of critical signaling pathways, particularly PI3K/Akt, JAK/STAT, NF-κB, MAPK/ERK, and Wnt/β-catenin. This review systematically examines subtype-specific responses to matrine treatment, highlighting its potential utility in precision oncology for distinct breast cancer classifications. Furthermore, we evaluate matrine's capacity to synergize with standard chemotherapeutic regimens, potentially overcoming drug resistance while reducing required dosages. By integrating current preclinical and clinical findings, this analysis provides new perspectives on matrine's therapeutic applications and underscores the imperative for translational studies to establish optimized treatment protocols for clinical implementation.

Indexed as

anti-tumorbreast cancermatrinemechanismtraditional Chinese medicine monomer

Identifiers

PMID40564074
PMCPMC12189624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.